Rocklatan Approval History
FDA Approved: Yes (First approved March 12, 2019)
Brand name: Rocklatan
Generic name: netarsudil and latanoprost
Dosage form: Ophthalmic Solution
Company: Aerie Pharmaceuticals, Inc.
Treatment for: Glaucoma, Open Angle, Intraocular Hypertension
Rocklatan (netarsudil and latanoprost ophthalmic solution) is a fixed dose combination of the Rho kinase inhibitor netarsudil (Rhopressa) and the prostaglandin analog latanoprost (Xalatan) indicated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Development History and FDA Approval Process for Rocklatan
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.